For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Teriparatide (recombinant human parathyroid hormone 1-34) therapy in myeloma patients with severe osteoporosis and fractures despite effective anti-myeloma therapy and bisphosphonates: A pilot study.

TitleTeriparatide (recombinant human parathyroid hormone 1-34) therapy in myeloma patients with severe osteoporosis and fractures despite effective anti-myeloma therapy and bisphosphonates: A pilot study.
Publication TypeJournal Article
Year of Publication2020
AuthorsDiamond TH, Golombick T, Manoharan A, Ramakrishna R, Bryant C
JournalAm J Hematol
Date Published2020 Jun 29
ISSN1096-8652
DOI10.1002/ajh.25919
Alternate JournalAm J Hematol
PubMed ID32602126